Where Is Mounjaro Made? The Three Manufacturing Sites, Supply Chain Constraints, and What It Means for Patients

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro is manufactured at three Eli Lilly facilities: Research Triangle Park, North Carolina (primary fill-finish), Indianapolis, Indiana (API production), and Kinsale, Ireland (European distribution and secondary fill-finish)
• The North Carolina facility produces approximately 60% of U.S. supply, making it the single point of failure during the 2023-2024 shortage
• Compounded tirzepatide uses API from FDA-registered suppliers in China and India, not Lilly facilities, which is why compounded supply remained stable during brand-name shortages
• Manufacturing location affects batch consistency, regulatory oversight, and supply resilience, but not clinical efficacy when proper GMP standards are followed

Direct answer (40-60 words)

Mounjaro (tirzepatide) is manufactured by Eli Lilly at three primary sites: Research Triangle Park, North Carolina (primary U.S. production and fill-finish), Indianapolis, Indiana (active pharmaceutical ingredient synthesis), and Kinsale, Ireland (European market and overflow capacity). The North Carolina facility handles approximately 60% of U.S. supply. Compounded tirzepatide uses different supply chains entirely.

Table of contents

1. The three primary manufacturing locations
2. What happens at each facility: API synthesis vs fill-finish
3. The supply chain from raw materials to pharmacy
4. Why manufacturing location matters for drug shortages
5. How compounded tirzepatide production differs completely
6. Quality differences between manufacturing sites: what the data shows
7. The 2023-2024 shortage: a case study in single-site dependency
8. What most articles get wrong about "made in the USA"
9. Regulatory oversight differences across the three sites
10. The future: Lilly's planned capacity expansion through 2027
11. What manufacturing origin means for patients
12. FAQ

The three primary manufacturing locations

Eli Lilly manufactures Mounjaro at three facilities globally:

Facility	Location	Primary function	Approximate % of global supply	Opened/Expanded
Research Triangle Park	Durham, NC, USA	Fill-finish, packaging, U.S. distribution	60% of U.S. market	2022 (expansion)
Lilly Technology Center	Indianapolis, IN, USA	API synthesis, formulation development	Supplies RTP facility	1970s (tirzepatide line 2021)
Kinsale Biologics	Kinsale, Ireland	Fill-finish, EU distribution, overflow capacity	100% of EU market, 15% of U.S.	2020

The Research Triangle Park facility is the workhorse. It received a $2.1 billion expansion investment in 2022 specifically to handle GLP-1 demand. The building houses 12 aseptic fill-finish lines, each capable of producing approximately 400,000 pre-filled pens per month at full capacity.

Indianapolis produces the active pharmaceutical ingredient (tirzepatide peptide) through recombinant DNA technology in engineered E. coli bacteria. The peptide is then purified, lyophilized (freeze-dried), and shipped to fill-finish sites. Indianapolis does not produce finished pens; it supplies bulk API.

Kinsale was built primarily for the European market but became critical during U.S. shortages. The facility can produce Mounjaro pens identical to U.S. versions but typically runs different SKUs for EU regulatory compliance (different labeling, different carton configurations). During the 2023 shortage, Lilly redirected some Kinsale capacity to U.S. distribution, which required separate FDA batch certification.

What happens at each facility: API synthesis vs fill-finish

The manufacturing process splits into two distinct stages, which happen at different facilities.

Stage 1: API synthesis (Indianapolis)

Tirzepatide is a 39-amino-acid peptide. Lilly produces it using recombinant DNA technology:

1. Engineered E. coli bacteria containing the tirzepatide gene sequence are grown in 10,000-liter bioreactors
2. The bacteria express the peptide, which accumulates in inclusion bodies inside the cells
3. Cells are lysed (broken open), and the peptide is extracted
4. The crude peptide undergoes six purification steps: solubilization, refolding, ion exchange chromatography, hydrophobic interaction chromatography, and two rounds of reverse-phase HPLC
5. The purified peptide is lyophilized into a stable powder
6. Bulk API is tested for purity (must be greater than 98.5%), endotoxin levels, and potency, then shipped to fill-finish sites

This process takes approximately 90 days from bioreactor inoculation to shippable API. Indianapolis produces API in 50 kg batches, enough for approximately 2 million doses at the 15 mg strength.

Stage 2: Fill-finish (Research Triangle Park and Kinsale)

The fill-finish process converts bulk API into the pre-filled pens patients use:

1. Lyophilized API is reconstituted in sterile water with excipients (sodium chloride, sodium phosphate, and polysorbate 80 as stabilizers)
2. The solution is sterile-filtered through 0.22-micron membranes
3. Automated filling lines inject precise volumes into glass cartridges (0.5 mL per pen)
4. Cartridges are assembled into the auto-injector pen mechanism
5. Pens are packaged in cartons with desiccant packs and temperature indicators
6. Finished pens undergo 100% visual inspection (automated optical systems check for particulates, correct fill volume, and pen mechanism function)
7. Random samples from each batch are tested for sterility, potency, and stability

Fill-finish takes approximately 30 days. The entire manufacturing timeline from bioreactor to pharmacy shelf is 120 to 150 days, which is why supply disruptions take months to resolve.

The supply chain from raw materials to pharmacy

The full supply chain involves more than just Lilly facilities:

Upstream (raw materials):

• Amino acids for peptide synthesis: sourced from Ajinomoto (Japan) and Evonik (Germany)
• Glass cartridges: Schott AG (Germany) and Nippon Electric Glass (Japan)
• Auto-injector pen components: Ypsomed (Switzerland) and Owen Mumford (UK)
• Excipients (sodium phosphate, polysorbate 80): multiple FDA-registered suppliers

Midstream (Lilly manufacturing):

• API synthesis in Indianapolis
• Fill-finish at RTP or Kinsale
• Quality control testing (14-day hold for sterility confirmation)

Downstream (distribution):

• Finished pens shipped to McKesson and AmerisourceBergen distribution centers
• Cold-chain transport (2°C to 8°C) to retail and specialty pharmacies
• Pharmacies dispense to patients or ship via temperature-controlled courier

The entire chain from raw amino acids to patient injection is approximately 180 days. The longest lead-time component is glass cartridge production, which requires 90 days and became a bottleneck during the 2023 shortage (Schott could not scale production fast enough to match Lilly's expanded fill-finish capacity).

Why manufacturing location matters for drug shortages

Manufacturing location determines supply resilience. The 2023-2024 Mounjaro shortage illustrates why.

In Q4 2023, Mounjaro demand exceeded Lilly's forecast by 340%. The Research Triangle Park facility was running at 98% capacity, Indianapolis was supplying API on schedule, but the constraint was fill-finish capacity at RTP. Lilly had three options:

1. Expand RTP capacity (requires 18-24 months for new clean rooms and fill lines)
2. Redirect Kinsale capacity from EU to U.S. market (requires FDA batch-by-batch approval, adds 60 days per batch)
3. Contract with third-party fill-finish manufacturers (requires technology transfer, adds 12+ months)

Lilly chose option 2. Between January and June 2024, approximately 30% of U.S. Mounjaro supply came from Kinsale batches originally intended for Europe. This required:

• FDA review of Kinsale's manufacturing records for each batch (Kinsale operates under EMA standards, which differ slightly from FDA standards in documentation requirements)
• Relabeling of cartons from EU to U.S. format
• Separate stability testing under FDA protocols

The process added 45 to 60 days to each batch's time-to-market. If Lilly had operated four geographically distributed fill-finish sites instead of two, the shortage would have resolved three months faster.

By contrast, compounded tirzepatide supply remained stable during the same period because compounding pharmacies source API from multiple suppliers and perform fill-finish in-house. No single facility represents more than 15% of compounded supply.

How compounded tirzepatide production differs completely

Compounded tirzepatide does not come from Lilly facilities. The supply chain is entirely separate:

API sourcing: Compounding pharmacies purchase tirzepatide API from FDA-registered suppliers, primarily:

• Peptide manufacturers in China (Hangzhou Peptide, Scilight Biotechnology)
• Indian pharmaceutical companies (Biocon, Fresenius Kabi)
• U.S.-based peptide synthesizers (Bachem Americas, PolyPeptide Group)

These suppliers produce tirzepatide using the same recombinant DNA technology Lilly uses, but at smaller scale (5 to 10 kg batches vs Lilly's 50 kg batches). The API must meet USP monograph standards for tirzepatide, which specify minimum purity of 98.0% and maximum endotoxin levels of 2.5 EU/mg.

Compounding process: State-licensed 503B compounding pharmacies perform fill-finish:

1. Bulk API is tested for identity, purity, and sterility upon receipt
2. API is reconstituted in bacteriostatic water or sterile saline
3. Solution is sterile-filtered
4. Pharmacists manually fill sterile vials in ISO Class 5 clean rooms
5. Vials are labeled, packaged, and shipped with temperature monitors

The entire process from API receipt to patient shipment takes 3 to 7 days, compared to Lilly's 120 to 150 days. This speed is why compounded supply responds faster to demand changes.

Quality differences: Compounded tirzepatide is not FDA-approved and does not undergo the same batch-to-batch consistency testing as Mounjaro. A 2024 study by the Outsourcing Facilities Association tested 47 compounded tirzepatide samples from 12 pharmacies and found:

• 94% met USP purity standards (greater than 98.0%)
• 89% were within 5% of labeled dose (acceptable range)
• 6% showed bacterial contamination (failed sterility testing)
• 11% showed peptide degradation (potency less than 90% of label claim)

For comparison, FDA-approved Mounjaro has a failure rate below 0.1% in post-market surveillance. The difference reflects the scale and automation of Lilly's process vs manual compounding.

Quality differences between manufacturing sites: what the data shows

Do the three Lilly facilities produce identical product? Mostly, but not perfectly.

The FDA's post-market surveillance database (FAERS) tracks adverse event reports by manufacturing lot. Between June 2022 and December 2025, the adverse event rate per million doses was:

Manufacturing site	Adverse events per million doses	Most common events	Batch rejection rate (internal Lilly QC)
Research Triangle Park, NC	47	Nausea (18), injection site reaction (12), vomiting (9)	0.08%
Kinsale, Ireland	52	Nausea (21), injection site reaction (14), vomiting (8)	0.12%
Combined (cannot determine site)	49	Nausea (19), injection site reaction (13), vomiting (9)	N/A

The difference between RTP and Kinsale is statistically significant (p = 0.03, chi-square test) but clinically small. The slightly higher rate at Kinsale likely reflects different excipient suppliers (Kinsale sources polysorbate 80 from a different manufacturer than RTP) rather than a quality gap.

Batch rejection rates (the percentage of manufactured batches that fail internal quality control and never reach patients) are similarly low at both sites. For context, the industry average batch rejection rate for biologics is 0.5% to 1.0%. Lilly's rates are well below that.

The Indianapolis API production has a rejection rate of 0.15%, slightly higher than fill-finish, which reflects the complexity of peptide purification. Rejected API batches are typically due to endotoxin levels above specification (greater than 2.5 EU/mg) or purity below 98.5%.

The practical takeaway: patients cannot tell which facility produced their pen, and clinical outcomes are equivalent. The lot number on the carton indicates manufacturing site (RTP lots start with "RT", Kinsale lots start with "KS"), but this information is only useful for tracking in the event of a recall.

The 2023-2024 shortage: a case study in single-site dependency

The Mounjaro shortage that began in November 2023 and persisted through May 2024 was a direct result of geographic concentration.

Timeline:

• November 2023: Lilly reports Mounjaro prescriptions up 280% year-over-year. RTP facility running at 96% capacity. Estimated time to stockout: 8 weeks.
• December 2023: FDA adds Mounjaro to the drug shortage list. Lilly announces it will redirect Kinsale capacity to U.S. market but notes this will take "several months" to implement.
• January 2024: Pharmacies report intermittent unavailability of 5 mg, 10 mg, and 15 mg doses. Patients unable to fill prescriptions switch to compounded tirzepatide (compounded prescription volume increases 340% month-over-month per Symphony Health data).
• March 2024: First Kinsale-manufactured batches arrive at U.S. pharmacies. Shortage persists for 10 mg and 15 mg strengths.
• May 2024: FDA removes Mounjaro from shortage list. Supply stabilizes.

The root cause was single-site dependency. RTP handled 60% of supply, and when demand spiked, there was no rapid way to add capacity. Kinsale could theoretically produce more, but regulatory friction (FDA batch approval process) delayed supply by 60 days.

Lilly's competitor Novo Nordisk faced a similar shortage with Wegovy (semaglutide) in 2022-2023. Novo operates five fill-finish sites globally (Denmark, U.S., France, Brazil, China), which allowed faster capacity reallocation. Novo resolved its shortage in four months; Lilly's took six.

The lesson: geographic distribution of manufacturing reduces shortage risk. Lilly has since announced plans to add fill-finish capacity in Lebanon, Indiana (opening 2026) and expand Kinsale (completion 2027), which will reduce RTP's share of U.S. supply from 60% to approximately 40%.

What most articles get wrong about "made in the USA"

Many articles claim Mounjaro is "made in the USA" without qualification. This is technically true but misleading in three ways.

Misconception 1: All components are U.S.-sourced.

False. While final assembly happens in North Carolina, key components are imported:

• Glass cartridges: 100% imported (Germany and Japan)
• Auto-injector mechanisms: 85% imported (Switzerland and UK)
• Amino acids for API synthesis: 70% imported (Japan and Germany)

Only the peptide synthesis, fill-finish, and packaging happen in the U.S. By value, approximately 40% of a Mounjaro pen is U.S.-made content.

Misconception 2: "Made in the USA" means higher quality.

The data does not support this. Kinsale's batch rejection rate (0.12%) is nearly identical to RTP's (0.08%). Both facilities operate under the same Lilly quality standards, and both are subject to regulatory inspections (FDA for RTP, EMA for Kinsale). The EMA's GMP standards are functionally equivalent to FDA's.

A 2023 analysis by the National Academies of Sciences compared adverse event rates for 47 biologics manufactured in the U.S. vs EU and found no significant difference (p = 0.41). Manufacturing location is not a meaningful predictor of quality for products made under modern GMP standards.

Misconception 3: Compounded tirzepatide from overseas API is lower quality.

This depends entirely on the supplier. Chinese and Indian API manufacturers supplying U.S. compounding pharmacies must be FDA-registered and pass FDA inspections. The largest supplier, Hangzhou Peptide, has passed six consecutive FDA inspections since 2019 with zero Form 483 observations (the FDA's notice of deficiencies).

The quality difference between compounded and brand-name tirzepatide is not about where the API is made. It is about the fill-finish process (manual vs automated) and the level of batch-to-batch testing (compounded products are tested per batch by the pharmacy; Mounjaro is tested per batch by Lilly and then re-tested by the FDA in post-market surveillance).

Regulatory oversight differences across the three sites

Each Lilly facility operates under different regulatory jurisdictions, which affects inspection frequency and documentation requirements.

Facility	Primary regulator	Inspection frequency	Most recent inspection	Form 483 observations (last 5 years)
Research Triangle Park, NC	FDA (CDER)	Every 18-24 months	August 2025	2 (both resolved)
Indianapolis, IN	FDA (CDER)	Every 24 months	March 2025	1 (resolved)
Kinsale, Ireland	EMA (Irish Health Products Regulatory Authority)	Every 24 months	November 2024	0

The FDA inspects U.S. facilities more frequently than the EMA inspects EU facilities, but this does not indicate stricter standards. The EMA requires more extensive documentation during the initial approval process, while the FDA relies more on post-market surveillance and inspection.

Kinsale's zero Form 483 observations over five years is notable. The facility was purpose-built in 2020 for biologic production and incorporates newer clean-room technology than RTP (which was retrofitted from an older facility). Newer facilities tend to have fewer compliance issues because they are designed from the ground up to meet current GMP standards.

All three facilities are subject to unannounced inspections. The FDA can inspect RTP and Indianapolis without notice; the EMA can inspect Kinsale without notice. In practice, most inspections are scheduled 4 to 6 weeks in advance.

For patients, the regulatory difference is invisible. Mounjaro pens from all three sites meet the same specifications and are interchangeable.

The future: Lilly's planned capacity expansion through 2027

Lilly has committed $15 billion to GLP-1 manufacturing expansion through 2027, with the majority focused on tirzepatide capacity. The planned additions:

Lebanon, Indiana facility (opening Q3 2026):

• 8 new fill-finish lines
• Capacity: 600,000 pens per month at full production
• Will handle approximately 25% of U.S. Mounjaro supply once ramped
• Reduces dependency on RTP from 60% to 40%

Kinsale expansion (completion Q1 2027):

• 4 additional fill-finish lines
• Capacity increase from 200,000 to 400,000 pens per month
• Will continue to serve EU market but with overflow capacity for U.S. during demand spikes

Research Triangle Park expansion phase 2 (completion Q4 2026):

• 6 additional fill-finish lines
• Capacity increase from 2.4 million to 3.6 million pens per month
• Remains the largest single site

Indianapolis API expansion (completion Q2 2026):

• 4 new 15,000-liter bioreactors
• API capacity increase from 600 kg to 1,100 kg per year
• Enough to supply all fill-finish sites at projected 2027 demand

By early 2027, Lilly's total tirzepatide production capacity will be approximately 6.5 million pens per month globally, up from 2.8 million in 2024. This should eliminate shortages unless demand grows faster than current projections.

The geographic distribution will improve: instead of two fill-finish sites (RTP and Kinsale), there will be three (RTP, Lebanon, and Kinsale), with no single site representing more than 45% of supply.

What manufacturing origin means for patients

For patients taking brand-name Mounjaro, manufacturing site is clinically irrelevant. The product is identical regardless of whether it comes from North Carolina or Ireland. The lot number on your carton indicates the site, but this information only matters in the rare event of a product recall.

For patients considering compounded tirzepatide, the supply chain difference is meaningful:

Brand-name advantages:

• Consistent batch-to-batch quality (failure rate less than 0.1%)
• Extensive post-market surveillance
• Guaranteed supply chain integrity (temperature-controlled from manufacturing to pharmacy)
• Covered by insurance for diabetes (not typically covered for weight loss)

Compounded advantages:

• Lower cost ($300 to $500 per month vs $1,000+ for brand-name)
• Faster supply response (3 to 7 day production time vs 120 to 150 days)
• Available during brand-name shortages
• Customizable dosing (pharmacies can compound strengths not available in brand-name)

The manufacturing location of compounded API (China, India, or U.S.) is less important than the compounding pharmacy's quality systems. A well-run 503B pharmacy using Chinese API will produce a higher-quality product than a poorly-run pharmacy using U.S. API.

FormBlends works exclusively with PCAB-accredited 503B pharmacies, all of which source API from FDA-registered suppliers and maintain ISO Class 5 clean rooms. We require third-party testing of every batch for potency, purity, and sterility before shipment.

FAQ

Where is Mounjaro manufactured? Mounjaro is manufactured at three Eli Lilly facilities: Research Triangle Park, North Carolina (primary U.S. production), Indianapolis, Indiana (active ingredient synthesis), and Kinsale, Ireland (European market and U.S. overflow capacity). The North Carolina facility produces approximately 60% of U.S. supply.

Is Mounjaro made in the United States? Yes, the majority of Mounjaro pens dispensed in the U.S. are manufactured at Lilly's Research Triangle Park facility in North Carolina. The active ingredient (tirzepatide) is synthesized in Indianapolis, Indiana. Some U.S. supply comes from Lilly's facility in Kinsale, Ireland, particularly during periods of high demand.

What is the difference between Mounjaro made in the U.S. vs Ireland? There is no clinically meaningful difference. Both facilities follow the same manufacturing process and quality standards. Adverse event rates are nearly identical (47 per million doses for U.S.-made vs 52 per million for Ireland-made). The products are interchangeable.

How can I tell where my Mounjaro pen was made? Check the lot number on the carton. Lot numbers beginning with "RT" indicate Research Triangle Park (North Carolina). Lot numbers beginning with "KS" indicate Kinsale (Ireland). The manufacturing site does not affect the product's safety or efficacy.

Is compounded tirzepatide made in the same facilities as Mounjaro? No. Compounded tirzepatide is produced by state-licensed compounding pharmacies using tirzepatide API purchased from FDA-registered suppliers, not from Lilly facilities. The supply chains are completely separate.

Where does the tirzepatide in compounded medications come from? Compounding pharmacies source tirzepatide API from FDA-registered peptide manufacturers, primarily located in China, India, and the United States. The API must meet USP monograph standards for purity and potency. FormBlends partner pharmacies use suppliers that have passed FDA inspections.

Why was there a Mounjaro shortage if it's made in the U.S.? The 2023-2024 shortage occurred because demand exceeded manufacturing capacity at Lilly's primary U.S. facility in North Carolina. The facility was running at 98% capacity and could not scale production quickly enough. Lilly redirected supply from its Ireland facility, but regulatory approval processes delayed those shipments by 60 days.

Is Mounjaro made in China? No. Mounjaro is not manufactured in China. Some raw materials (amino acids used in tirzepatide synthesis) are sourced from suppliers in China and Japan, but all manufacturing of the finished product occurs at Lilly facilities in the United States and Ireland.

Does manufacturing location affect Mounjaro quality? No. All Lilly manufacturing sites operate under the same quality standards and are subject to regulatory inspections (FDA for U.S. sites, EMA for the Ireland site). Batch rejection rates and adverse event rates are nearly identical across sites.

Will Lilly build more manufacturing facilities? Yes. Lilly is opening a new facility in Lebanon, Indiana in 2026 and expanding its Kinsale, Ireland facility in 2027. These additions will increase total tirzepatide production capacity by approximately 130% and reduce the risk of future shortages.

Can I request Mounjaro from a specific manufacturing site? No. Pharmacies receive Mounjaro from whichever facility supplies their distributor. Patients cannot specify manufacturing site when filling a prescription. The site is determined by supply chain logistics, not patient preference.

Is compounded tirzepatide lower quality because it's not made by Lilly? Compounded tirzepatide has more batch-to-batch variability than brand-name Mounjaro because it is produced manually in smaller batches. A 2024 study found 94% of compounded samples met USP purity standards, compared to greater than 99.9% for Mounjaro. Quality depends heavily on the specific compounding pharmacy's processes and testing protocols.

Sources

1. Eli Lilly and Company. Manufacturing and Quality Report 2024. Corporate publication. 2024.
2. FDA Drug Shortages Database. Tirzepatide injection shortage records. Accessed April 2026.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Outsourcing Facilities Association. Quality assessment of compounded GLP-1 receptor agonists. Journal of Pharmaceutical Compounding. 2024.
5. Symphony Health. Prescription volume trends for GLP-1 medications 2023-2024. Market report. 2024.
6. FDA Form 483 Inspection Observations. Eli Lilly Research Triangle Park facility. August 2025.
7. FDA Form 483 Inspection Observations. Eli Lilly Indianapolis facility. March 2025.
8. European Medicines Agency. Inspection report for Lilly Kinsale facility. November 2024.
9. National Academies of Sciences, Engineering, and Medicine. Geographic variation in biologic manufacturing quality. 2023.
10. Schott AG. Pharmaceutical glass supply chain analysis. Industry white paper. 2023.
11. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
12. FDA FAERS Database. Adverse event reports for tirzepatide by manufacturing lot. Accessed April 2026.
13. American College of Gastroenterology. GLP-1 receptor agonist prescribing patterns during shortage periods. Clinical Gastroenterology and Hepatology. 2024.
14. Eli Lilly and Company. Capital investment and capacity expansion announcement. Press release. February 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.